China Regenerative Medicine International (HKSE:08158) Debt-to-Revenue : N/A (As of Jun. 2024)

View and export this data going back to 2001. Start your Free Trial

What is China Regenerative Medicine International Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

China Regenerative Medicine International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$29.30 Mil. China Regenerative Medicine International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$21.58 Mil. China Regenerative Medicine International's annualized Revenue for the quarter that ended in Jun. 2024 was HK$0.00 Mil.

China Regenerative Medicine International Debt-to-Revenue Historical Data

The historical data trend for China Regenerative Medicine International's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Regenerative Medicine International Debt-to-Revenue Chart

China Regenerative Medicine International Annual Data

Trend

Apr15

Apr16

Apr17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Revenue

Get a 7-Day Free Trial

0.24

0.13

1.73

0.72

0.59

China Regenerative Medicine International Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial															0.38	-	N/A	N/A	N/A

Competitive Comparison of China Regenerative Medicine International's Debt-to-Revenue

For the Biotechnology subindustry, China Regenerative Medicine International's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Regenerative Medicine International's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Regenerative Medicine International's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where China Regenerative Medicine International's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

China Regenerative Medicine International Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

China Regenerative Medicine International's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(24.024	+	26.167)	/	69.487
	=	0.72

China Regenerative Medicine International's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(29.3	+	21.579)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2024) Revenue data.

China Regenerative Medicine International Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of China Regenerative Medicine International's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

China Regenerative Medicine International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Regenerative Medicine International Ltd (HKSE:08158) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

132 Nathan Road, Suite 2310-18, Miramar Tower, Tsim Sha Tsui, Kowloon, HKG

Website

https://www.crmi.hk

China Regenerative Medicine International Ltd is an investment holding company engaged in the provision of healthcare products and services. Its reportable segments are Aesthetic medical and beauty services and Medical services. The vast majority of the company's revenue is derived from its Aesthetic medical and beauty services segment. Geographically, the People's Republic of China accounts for the majority of the revenue. It also has a presence in Hong Kong.

Executives

Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Wang Chuang	2101 Beneficial owner
Arab Osman Mohammed	2501 Other
Wong Kwok Keung	2501 Other
Lei Changjuan	2101 Beneficial owner
Chang Zhou Shi Zhong Min Xing Kong Qi Ye Guan Li Zi Xun Fu Wu He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Kong Yudong	2101 Beneficial owner
Chang Zhou Shi Yao Guang Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Li Ren	2201 Interest of corporation controlled by you
Nat-ace Wood Industry Ltd. (formerly Known As Forerunner Technology Limited)	2201 Interest of corporation controlled by you
All Favour Holdings Limited	2101 Beneficial owner
Deng Shufen	2202 Interest of your spouse
Dai Yumin	2201 Interest of corporation controlled by you
Wang Xiaogang	2101 Beneficial owner
China Orient Asset Management Co., Ltd.	2106 Person having a security interest in shares

China Regenerative Medicine International Headlines

No Headlines